Interactions of insulin-like growth factor I with dexamethasone on trabecular bone density and mineral metabolism in rats

Binz, K.; Schmid, C; Bouillon, Roger; Froesch, E. R.; Jurgensen, Kimberly; Hunziker, E B

doi:10.1530/eje.0.1300387

Cited by 19 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In young rats, however, the cancellous bone volume of the vertebral body has been shown to be unchanged, both in adrenalectomized rats treated with GC release tablets (20) and in normal rats treated with depot GC (14) when compared with the saline controls. Likewise, the star volume of the vertebral body in young rats was unaffected by adding dexamethasone to the drinking water (22) . In the present study, daily injections with a short half‐life preparation of GC, however, arrested the development of cancellous bone volume in the vertebral body of young rats, resulting in similar values as in the baseline group.…”

Section: Discussioncontrasting

confidence: 40%

“…Other studies have examined the effect of GC on cancellous bone in both old (18, 19) and young rats (20‐23) with different results. In old rats, GC decreases the cancellous bone volume of the proximal tibia independent of whether a weekly depot preparation (19) or a daily injection (18) of GC are given.…”

Section: Discussionmentioning

confidence: 99%

“…In old rats, GC decreases the cancellous bone volume of the proximal tibia independent of whether a weekly depot preparation (19) or a daily injection (18) of GC are given. When continuous administration of GC is given to young normal rats (21, 22) or adrenalectomized rats, (20) the cancellous bone volume of the proximal tibia is increased, and in normal rats the cancellous bone volume of the proximal femur (23) is also increased, independent of whether GC is administered as infusion, (23) added to the drinking water, (22) or administered as inoperated release tablets (20, 21) . In young rats, however, the cancellous bone volume of the vertebral body has been shown to be unchanged, both in adrenalectomized rats treated with GC release tablets (20) and in normal rats treated with depot GC (14) when compared with the saline controls.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Growth Hormone Increases Cortical and Cancellous Bone Mass in Young Growing Rats with Glucocorticoid-Induced Osteopenia

Ørtoft

Andreassen

Oxlund

1999

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

The effects of growth hormone (GH) on linear growth, bone formation, and bone mass have been examined in glucocorticoid (GC)-injected young growing rats. Two-month-old female Wistar rats were injected for 90 days with 1, 3, 6, or 9 mg of methylprednisolone alone or in combination with 5 mg of GH. Bone mass and bone formation parameters were examined in the femoral cortical bone and in cortical bone and cancellous bone of the lumbar vertebra. GC administration dose dependently decreased growth, longitudinal growth of the vertebra, as well as the modeling drift of the cortical bone of the vertebral body and femoral diaphysis. In the vertebral cancellous bone, GC also decreased the mineralizing surface and inhibited the growth-related increase in cancellous bone volume. GH increased growth, longitudinal growth of the vertebra, as well as the modeling drift of the vertebral body and the femoral diaphysis, resulting in an increased cortical bone mass. GH also increased cancellous bone volume and the mineralizing surface of the vertebral body. In GC-injected animals, GH normalized and further increased growth, longitudinal growth, and the modeling drift of both the femoral diaphysis and the vertebral body, resulting in an increased cortical bone mass at both locations. GH also increased cancellous bone volume of the vertebral body in GC-injected animals, but GH did not, however, reverse the decreased mineralizing surface of cancellous bone induced by GC injections. In conclusion, GC administration to growing rats retards normal growth, longitudinal growth, and cortical bone modeling drift. It also decreases the cancellous bone mineralizing surface and inhibits the normal age-related increase in cancellous bone volume of the vertebral body. In the growing rat skeleton, GH can counteract these GC-induced side effects, except for the GC-induced decrease in the mineralizing surface of cancellous bone of the vertebral body, which remained unaffected by GH administration. (J Bone Miner Res 1999;14:710-721)

show abstract

Section: Discussioncontrasting

confidence: 40%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Growth Hormone Increases Cortical and Cancellous Bone Mass in Young Growing Rats with Glucocorticoid-Induced Osteopenia

Ørtoft

Andreassen

Oxlund

1999

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

show abstract

“…There have been few studies in which IGF‐I has been given to glucocorticoid‐treated animals. Infusion of IGF‐I (0.3 μg/day) into dexamethasone‐treated mice did not affect trabecular bone formation (62) . It is likely that the ability of in vivo IGF‐I to increase bone formation in glucocorticoid‐treated animals will depend on the dose, frequency of the dosage, and whether or not it is complexed to IGFBP.…”

Section: Discussionmentioning

confidence: 98%

Modulation of the Effects of Glucocorticoids on Collagen Synthesis in Fetal Rat Calvariae by Insulin-like Growth Factor Binding Protein-2

Kream

Tetradis

LaFrancis

et al. 1997

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

show abstract

“…After initiation of steroid therapy, in most cases the protein losses regress quickly. This leaves only the effects of the glucocorticoid treatment, which alters growth by a direct action on the growth cartilage [5,6,7,8] or via disturbances of growth factors [9,10,11].…”

Section: Introductionmentioning

confidence: 99%

Growth in steroid-responsive nephrotic syndrome: a study of 85 pediatric patients

Donatti

Koch

Fujimura

et al. 2003

Pediatric Nephrology

View full text Add to dashboard Cite

The statural growth of 85 patients with steroid-responsive idiopathic nephrotic syndrome, attending the Pediatric Nephrology Unit, Children's Institute, Hospital das Clínicas School of Medicine, University of São Paulo, with a minimum follow-up of 3 years, was evaluated. Analysis of the patient population as a group did not show any significant alterations in the height Z score and the mean height percentile between the first (-0.59 and 33.9, respectively) and last consultation (-0.57 and 34.8, respectively). Analysis of each individual patient allowed the definition of two subgroups. Subgroup A, which achieved growth improvement, was composed of 47 children-initial Z score and mean initial height percentile of -0.91 and 24.0, respectively; final Z score and mean height percentile of -0.30 and 40.7, respectively ( P=0.00). Subgroup B, which showed growth retardation, was composed of 38 children-initial Z score and mean initial height percentile of -0.19 and 46.2, respectively; final Z score and mean height percentile of -0,9 and 27.5, respectively ( P=0.00). The following factors were significantly different when both subgroups were compared: (1) total duration of prednisone therapy and total prednisone dose were greater in subgroup B; (2) the final chronological age of patients using prednisone was higher in subgroup B; (3) the pubertal growth spurt in subgroup B showed attenuation and retardation.

show abstract

Interactions of insulin-like growth factor I with dexamethasone on trabecular bone density and mineral metabolism in rats

Cited by 19 publications

References 0 publications

Growth Hormone Increases Cortical and Cancellous Bone Mass in Young Growing Rats with Glucocorticoid-Induced Osteopenia

Growth Hormone Increases Cortical and Cancellous Bone Mass in Young Growing Rats with Glucocorticoid-Induced Osteopenia

Modulation of the Effects of Glucocorticoids on Collagen Synthesis in Fetal Rat Calvariae by Insulin-like Growth Factor Binding Protein-2

Growth in steroid-responsive nephrotic syndrome: a study of 85 pediatric patients

Contact Info

Product

Resources

About